First Tracks Biotherapeutics (TRAX) Q3 2026 earnings review
First Tracks proves its celiac drug works and doubles cash
First Tracks Biotherapeutics proved its lead immune drug works in celiac disease and used the win to refill its bank account. The clinical-stage biotech group reported that ANB033 protected patients from gut damage and symptoms during a six-week gluten test, and chief executive Daniel Faga immediately raised $200 million to lift pro forma cash to $343 million. Quarterly operating expenses fell 27% from a year ago to $33 million as the company wound down older trials following its April spin-off from AnaptysBio.
| Pro forma cash after October raise | $343M up from $155.6M at Q3 end |
|---|---|
| ANB033 celiac gut lining score | +0.49 advantage over placebo (p=0.009) |
| Quarterly operating expenses | $32.8M -27% from a year ago |
| 2027 clinical trial plan | Expanded late-stage celiac trial added for 2027 |
⚖️ Verdict: 🟢 Bullish
The story got much better because the celiac trial succeeded on both tissue damage and patient symptoms, turning an early clinical concept into a late-stage program backed by more than twice as much cash. One caution: the company's other two drugs, rosnilimab and ANB101, remain stalled without active trials, leaving the entire investment case riding on ANB033.
The question now is whether ANB033 can heal existing gut damage in celiac patients as well as it blocks damage from a short gluten challenge. If it heals tissue, the drug could treat a wide group of patients with ongoing symptoms; if it only prevents acute flare-ups, its medical role is smaller. Top-line data from the fully enrolled second celiac group in the first quarter of 2027 will decide.
🐂 Bull Case
ANB033 Protects Celiac Patients Against Gluten Damage
First Tracks Biotherapeutics develops antibody medicines for immune diseases. Its lead drug candidate is ANB033, an injected medicine that blocks two immune signals called IL-15 and IL-2. In October, the company reported results from the first group in its Phase 1b celiac disease study, which tested whether the drug protects the gut during a six-week gluten challenge.
The medicine met its goals and "achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms", the biotech group said. Chief executive Daniel Faga added that "These data support our plans to progress ANB033 into late-stage development in 2027 in celiac disease".
- Gut lining structure (villus height-to-crypt depth ratio): fell 0.17 on ANB033 versus 0.66 on placebo, a 0.49 advantage
- Inflammatory white blood cells (intraepithelial lymphocyte density): fell 1.20 on ANB033 versus an 18.83 rise on placebo
- Safety profile: "Well tolerated with no safety signals observed" and lower symptom scores from day one
What to watch: results from the second group of the celiac study in the first quarter of 2027. That 12-week test measures whether ANB033 heals existing gut damage, which would broaden the drug's commercial reach beyond preventing accidental gluten reactions.
Private Placement More Than Doubles Cash Balances
Clinical-stage drug developers depend on cash reserves because they do not sell approved products yet. First Tracks ended September with $155.6 million in cash and investments, down 7.4% from $168.0 million in June as it burned $12.4 million during the third quarter by our math.
Immediately after reporting positive celiac disease data in October, management raised $200 million in gross proceeds through a private placement. That financing lifted pro forma cash to $343 million, an increase of 120.4% over the September balance by our math. At the third-quarter operating expense pace of $32.8 million, the new reserve covers 10.4 quarters of spending by our math, removing near-term funding risk before major trials begin.
What to watch: the exact share count and net proceeds from the October financing in the third-quarter filing. A large share issuance will increase the denominator for future per-share results and show the price institutional buyers paid.
Standalone R&D Spending Drops as Pipeline Refocuses
Total operating expenses fell 27.1% from a year ago to $32.8 million, and decreased 6.0% from the second quarter by our math. Research and development spending led the drop, falling 28.4% from a year ago to $23.8 million and shrinking 7.0% from last quarter.
The company said the drop came from "decreased development costs for rosnilimab and ANB032, offset by increased costs relating to the Phase 1 trial for ANB033". General and administrative overhead also declined 23.3% from a year ago to $9.0 million. Because First Tracks paused spending on older programs, its quarterly net loss narrowed to $31.4 million from $41.9 million a year earlier.
What to watch: fourth-quarter research and development expenses. With enrollment now finished in the second celiac disease cohort, research spending should stay near current levels until the new Phase 2 trials start in the first half of 2027.
🐻 Bear Case
Two Other Drug Candidates Sit Without Active Trials
First Tracks describes itself as a biotechnology company advancing a pipeline of three antibody medicines: ANB033, rosnilimab, and ANB101. In practice, only ANB033 is currently treating patients in active clinical studies, leaving the company reliant on a single drug for all near-term value.
For rosnilimab, an immune-cell depleter for rheumatoid arthritis that finished Phase 2 meetings early in 2026, the company repeated for a third straight quarter that it is "Currently assessing return-on-equity-maximizing strategic options to progress the potential development of rosnilimab in rheumatoid arthritis and other indications". Meanwhile, ANB101, an antibody for autoimmune diseases, finished its healthy-volunteer study, but management is waiting for "competitor registrational data in systemic lupus erythematosus and cutaneous lupus erythematosus anticipated in Q4 2026 and early 2027, respectively" before choosing a path.
What to watch: a partnership announcement for rosnilimab or a trial design for ANB101 in early 2027. If neither arrives after rivals report lupus data, First Tracks will remain a single-asset company.
Four New Trials Will Test Lower Cash Burn
While quarterly operating expenses dropped to $32.8 million in the third quarter, the clinical workload for ANB033 is about to expand. Faga plans to move ANB033 into a late-stage celiac disease trial in 2027, while also starting Phase 2 studies in the skin disease vitiligo and one unnamed condition during the first half of 2027.
Running a late-stage registration trial alongside two Phase 2 studies and an ongoing 50-patient eosinophilic esophagitis trial costs much more than a 60-patient Phase 1b study. Notably, the third-quarter release did not give an updated cash-runway end date after the $200 million raise, whereas the second-quarter release explicitly projected cash lasting into the second quarter of 2028.
What to watch: management's updated cash-runway timeline once the FDA agrees on the late-stage celiac trial design in 2027. The size of that pivotal study will determine how fast the $343 million cash pile shrinks.
👓 Other Themes
April Spin-Off Distorts Year-Over-Year Expense Comparisons
First Tracks separated from its former parent, AnaptysBio, on April 20, 2026. Because of accounting rules for spin-offs, financial figures before that date include shared parent expenses and legal bills from AnaptysBio's lawsuit with GSK and Tesaro. That pushed nine-month general and administrative costs up 31.8% to $37.1 million, making second-quarter and third-quarter numbers the only clean readings of standalone costs.
💲 Other KPIs
Weighted-average shares rose 28.4% from 27.83 million a year ago and increased 2.1% from 35.00 million in the second quarter by our math. The higher share count following the April separation spread the net loss over more shares, cutting the third-quarter loss per share by 41.3% to $0.88. This count does not yet include shares sold in October's $200 million placement.
Accrued expenses — bills recorded for clinical trial and operating work not yet paid in cash — rose 57.2% from $7.46 million in the second quarter, though they remain 54.6% below the $25.83 million level from December 2025 by our math. The third-quarter increase conserved cash and explains why net cash burn was $12.4 million despite a $31.4 million net loss.
Interest earned on cash reserves fell 53.3% from $3.20 million a year ago and edged down 4.4% from $1.56 million in the second quarter by our math. The decline tracked the smaller cash pile left after the April spin-off, though October's $200 million cash infusion will lift interest earnings starting in the fourth quarter.
🔮 Guidance
Unchanged. The company still expects top-line results from the 12-week mucosal-healing cohort in the first quarter of 2027. Importantly, management completed patient enrollment for this cohort during the recent period, removing enrollment delay risk.
New. Following October's positive Cohort 1 protection results and existing FDA Fast Track status, Faga plans to consult regulators and start a late-stage celiac disease trial in 2027.
Unchanged. The timeline to start Phase 2 testing in two new diseases during the first half of 2027 remains intact, and management named vitiligo as the first of those two targets for the first time.
Unchanged. Enrollment continues in the 50-patient, 12-week trial testing ANB033 against placebo for eosinophilic esophagitis, an allergic swallowing disorder. Top-line results remain on track for the third quarter of 2027 after shifting from mid-2027 earlier this year.
Unchanged. First Tracks is still waiting for rival late-stage data in systemic lupus erythematosus in the fourth quarter of 2026 and cutaneous lupus in early 2027 before deciding whether to advance ANB101.
❓ Key Questions
How many shares were issued in October's $200 million placement?
The press release disclosed $200 million in gross proceeds and $343 million in pro forma cash, but did not state the number of shares or warrants issued. Investors need the new share count to calculate ownership dilution.
How far into the future does the $343 million last?
In the second quarter, management projected cash lasting into the second quarter of 2028 on $168 million. After adding $200 million and planning a late-stage celiac trial for 2027, the company gave no updated runway date.
What is the fourth disease target for ANB033 in 2027?
Faga named vitiligo as one of the two new Phase 2 trials starting in the first half of 2027, alongside celiac disease and eosinophilic esophagitis, but left the fourth disease unnamed.
Why has the rosnilimab strategic review taken three quarters?
First Tracks finished its FDA end-of-Phase 2 meeting for rosnilimab in rheumatoid arthritis during the first quarter of 2026. Six months later, management has still not announced a partner, buyer, or trial plan.